MET and non-small cell lung carcinoma: Mechanisms of acquired resistance to EGFR-TKI in NSCLC are secondary mutations in EGFR itself, including the EGFR T790M mutation (about 50%) and amplification of the MET oncogene (15–20%) [44–45].